Clinical guidelines for targeted therapy of rare variants in primary lung cancer in China(2024 edition)
Currently,lung cancer ranks first in both incidence and mortality rate among malignancies in China.The discovery of oncogenic driver mutations provides a powerful strategy for precision medicine.Targeted therapies have become an essential treatment in guidelines worldwide.Emerging rare variants-targeted drugs improve patient survival effectively.Following the World Health Organization's Handbook for Guidelines Development,this guide integrates rare variants detection assay and new progress in clinical research on therapeutic drugs,combines domestic and foreign diagnosis and treatment guidelines with China's national conditions and clinical practices,and formulates the guideline for the clinical diagnosis and treatment of primary lung cancer targeted therapy for rare variants in China.This guideline aims to standardize the clinical practice of rare variants diagnosis and treatment of lung cancer,improve the standardized diagnosis and treatment system,and improve the level of lung cancer diagnosis and treatment in China.
NETL
NSTL
万方数据
